Atopic Dermatitis / Atopic Eczema – Landscape & Forecast – Disease Landscape & Forecast (G7)

Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate the itch. Topical therapies are often effective for mild disease but have suboptimal safety, tolerability, and compliance. The AD therapy market has undergone upheaval, beginning with the 2017 launches of Sanofi / Regeneron’s injectable biologic Dupixent and Pfizer’s nonsteroidal topical cream Eucrisa. Since then, multiple agents have been approved, including oral JAK inhibitors (Eli Lilly’s Olumiant, AbbVie’s Rinvoq, and Pfizer’s Cibinqo); nonsteroidal topical agents (Japan Tobacco’s Corectim, Incyte’s Opzelura, Otsuka / Acrotech Biopharma’s Moizerto, Arcutis’s Zoryve, and Organon / Dermavant / Japan Tobacco / Torii’s Vtama); an IL-31 inhibitor (Galderma / Maruho’s Mitchga / Nemluvio); and IL-13 inhibitors (Leo Pharma’s Adbry / Adtralza and Eli Lilly / Almirall’s Ebglyss). This report provides a comprehensive analysis of AD patient populations, current disease management, unmet needs, and the potential of current and emerging drugs.

Questions answered

• What are the sizes of the mild, moderate, and severe AD subpopulations, and how will they change by 2034? How well are they served by current AD therapies?
• How have Dupixent and other biologics been incorporated into the AD treatment algorithm? What market niches are oral JAK inhibitors (e.g., Cibinqo, Rinvoq, Olumiant), topicals (e.g., Corectim, Opzelura, Moizerto, Zoryve, Vtama), and other biologics (e.g., Adbry / Adtralza, Mitchga / Nemluvio, Ebglyss) beginning to occupy?
• What therapies are in development for AD? Of these therapies, which are best poised to achieve commercial success?
• What are the greatest unmet needs in the treatment of AD, and to what degree will therapies in the pipeline address these needs

Content highlights

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan

Primary research: 16 country-specific interviews with thought leaders; supported by survey data collected for this and other Clarivate research

Epidemiology: Diagnosed and drug-treated prevalence of AD by country, 12-month total and diagnosed prevalence of AD by severity

Forecast: 10-year, annualized, drug-level sales and patient share of key AD therapies through 2034, segmented by brands / generics, disease severity, and pediatric / adult subpopulations

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.